Ryght AI launched a clinical trial site “search engine” aimed at compressing site selection timelines by ranking research centers using disease expertise and other study-fit inputs. The company says the tool can cut campaigns that typically take six months to 26 days and cites an 89.5% engagement rate from contacted sites in a case study. The platform is publicly accessible and draws on a database of 100,000 sites across 192 countries, with an AI “agent” that scores options based on filters including biomarker expertise and trial phase. The rollout follows Ryght’s earlier funding from Accenture’s investment wing and positions AI for a practical, operational bottleneck that affects trial speed and cost well before first patient is enrolled.